8 active not recruiting, 7 completed, 1 recruiting. 13 Phase 2, 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Active not recruiting 8, Completed 4, Recruiting 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Recurrent Soft Tissue Sarcoma: new trials by email Literature Review of Recurrent Soft Tissue Sarcoma trials Research Report on Recurrent Soft Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography - Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma | Completed | Mayo Clinic | 9 | 2022-11-10 | 2025-07-10 | |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma CEB-01 membrane loaded with SN-38 - Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma | Phase 1 | Completed | CEBIOTEX | 21 | 2020-06-03 | 2026-05-12 |
| Radiotherapy With Hyperthermia in Recurrent and Radiation-Induced Sarcomas Hypofractionated radiotherapy, Hyperthermia, Hypofractionated radiotherapy with boost - Radiation Induced Neoplasms, Radiation-Induced Cancer | Not applicable | Completed | Maria Sklodowska-Curie National Research Institute of Oncology | 20 | 2019-10-23 | 2025-04-30 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma Pembrolizumab, Radiation Therapy - Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 27 | 2018-03-28 | 2024-07-23 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-11-12 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
Sarcoma (16) · Hepatoblastoma (12) · Osteosarcoma (12) · Rhabdomyosarcoma (12) · Wilms Tumor (12) · Neuroblastoma (11) · Neuroectodermal Tumors, Primitive, Peripheral (11) · Rhabdoid Tumor (11) · Ependymoma (10) · Glioma (10) · Histiocytosis, Langerhans-Cell (10) · Lymphoma, Non-Hodgkin (10) · Medulloblastoma (10) · Sarcoma, Ewing (10) · Central Nervous System Neoplasms (6)
Neoplasms by Histologic Type (16) · Neoplasms, Connective and Soft Tissue (16) · Neoplasms (15) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Genetic Diseases, Inborn (12) · Kidney Diseases (12) · Kidney Neoplasms (12) · Male Urogenital Diseases (12) · Myosarcoma (12) · Neoplasms by Site (12) · Neoplasms, Bone Tissue (12) · Neoplasms, Complex and Mixed (12) · Neoplasms, Connective Tissue (12)
Magnetic Resonance Spectroscopy (6) · Phantoms, Imaging (5) · X-Rays (5) · Nuclear Medicine Department, Hospital (4) · Specimen Handling (4) · Biopsy (3) · LY3023414 (2) · Radiation (2) · Radiotherapy (2) · ensartinib (2) · ivosidenib (2) · larotrectinib (2) · palbociclib (2) · selpercatinib (2) · tazemetostat (2)
National Cancer Institute (NCI) (11) · CEBIOTEX (1) · Fred Hutchinson Cancer Center (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Mayo Clinic (1) · St. Jude Children's Research Hospital (1)
United States (14) · Puerto Rico (10) · Australia (4) · Canada (3) · Poland (1) · Spain (1)
Ana Sebio, M.D. Ph.D. (1) · Andrea T Franson (1) · Christine A Pratilas (1) · Deanna Hasenauer, Ph.D. (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Katherine A Janeway (1) · Kieuhoa T Vo (1) · Lee Cranmer (1) · Meredith S Irwin (1) · Rajen Mody (1) · Sara Federico, MD (1) · Srivandana Akshintala (1) · Susan N Chi (1)
PMID 31401903, PMID 33591402, PMID 34486544, PMID 35353553, PMID 38935895, PMID 39298716, PMID 41166674, PMID 41984420, PMID 41984421, PMID 41998462, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (11), 2018 (1)